Nanjing Kingsray Biotechnology Co., Ltd. is a foreign enterprise.
Kingsray is a biopharmaceutical R&D outsourcing service company with a global scale of operation and international leading position. It also has branches in China, France and Japan. Kingsray's customer base has reached more than 5,700 customers and 130,000 laboratories in more than 100 countries and regions worldwide. Sixty percent of our clients are pharmaceutical and biotechnology companies, and the top 20 pharmaceutical companies in the world are Kingsray's partners.
Extended Information:
I. Market Opportunities
Over the past decade or so, the number of innovative drugs developed by pharmaceutical companies has been declining rapidly, while on the contrary their R&D expenditures have been increasing at a rapid pace. Reducing R&D expenses and shortening the R&D cycle of drugs are the same challenges faced by pharmaceutical companies around the world, and therefore the market for pharmaceutical R&D outsourcing services is expanding dramatically.
Based on the perfect production line, complete one-stop service, continuous improvement of workflow and strict intellectual property protection measures, Kingsley has established four major service platforms, namely, biological research reagents, new drug screening, target drug optimization, and antibody drug R&D, which ensures that pharmaceutical R&D personnel are provided with perfect outsourcing services.
II. Company Milestones
Established in 2002 in New Jersey, USA; started to provide comprehensive gene services in 2002; established a branch office in China in 2004; started to provide protein services for customers in 2004; started to provide peptide services for customers in 2004; started to provide antibody services for customers in 2005; and in 2008 became the biggest gene synthesis provider.
In 2008, we established a CRO service platform for biological research reagents, new drug screening, target drug optimization and antibody drug development for our customers; in 2008, Kingsray launched a series of the most advanced guaranteed-antibody services in the industry; in 2009, with the increase in production capacity and the optimization of service technology, Kingsray became the largest Chinese biopharmaceutical
In 2009, Kingsray was accredited by AAALAC; in 2010, it was awarded the 10th "Future Star" of Chinese Enterprises; in 2011, it was the only commercial organization invited to participate in the global yeast genome synthesis program; in 2015, it was listed in Hong Kong (stock code: 1548); and in 2018, it joined hands with the company to launch a series of the most advanced guaranteed-antibody services in the industry. 1548); in 2018, joined hands with American academicians to form a biotechnology research and development company.
Baidu Encyclopedia - Nanjing Kingsley Biotechnology Co.